Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACP-044 Dose A · 1 trial · 2 indications
Pain (efficacy) assessments were recorded hourly (±15 minutes) for a 12-hour interval on Day 1 beginning immediately prior to the fifth dose (time 0) administered in the study. Pain assessments were continued every 3 hours during the subsequent 12 hour interval, and then every 6 hours thereafter until 72 hours, then once daily in the morning until the follow-up clinical visit. Pain assessments were also obtained immediately prior to the administration of rescue medication. A 0 to 10 Numeric Rating Scale of Pain Intensity (NRS) was used to assess the subject's pain. Subjects were asked: "Please describe your foot pain at the present time from 0 to 10 where "0" means "no pain at all" and "10" means "the worst pain imaginable." The area under the curve is generated using the following timepoints beginning immediately prior to the fifth dose (time 0): 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, and 24 hours.
| Arm | Type | Description |
|---|---|---|
| Drug - ACP-044 Dose A | EXPERIMENTAL | ACP-044 Dose A |
| Drug - ACP-044 Dose B | EXPERIMENTAL | ACP-044 Dose B |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| ACP-044 Dose A | DRUG | Oral dose of ACP-044 Dose A |
| ACP-044 Dose B | DRUG | Oral dose of ACP-044 Dose B |
| Placebo | DRUG | Oral dose of placebo |
Inclusion Criteria: * Male or female ≥18 and \<60 years of age at the time of Screening * Has a body mass index (BMI) \<40 kg/m2 * Able to understand and provide signed informed consent * Able to complete subject-reported outcome measures * Is in need of a primary unilateral, first metatarsal bunio...